Medscape is available in 5 Language Editions – Choose your Edition here.


Recurrent Pyogenic Cholangitis

  • Author: Praveen K Roy, MD, AGAF; Chief Editor: Julian Katz, MD  more...
Updated: Jul 24, 2015


Cholangiohepatitis, or recurrent pyogenic cholangitis (RPC), is characterized by a recurrent syndrome of bacterial cholangitis that occurs in association with intrahepatic pigment stones and intrahepatic biliary obstruction. It was first described in 1930 and has been called by different names, including Hong Kong disease, Oriental cholangitis, and Oriental infestational cholangitis.



Recurrent episodes of cholangitis develop as a result of pyogenic bile duct infection. Predominantly coliform-type bacteria are seeded into the biliary system, and, as a consequence, a cascade of stone formation and recurrent cholangitis is initiated. The bile ducts of patients with cholangiohepatitis are thought to be increasingly susceptible to bacterial seeding as a result of helminthic infections or as a consequence of malnutrition.

Malnutrition results in a relative deficiency of enzymes, such as beta-glucuronidase inhibitor glucaro-1,4-lactone, that inhibit deconjugation of conjugated bilirubin. The relatively unopposed deconjugation favors breakdown of conjugated bilirubin to its unconjugated form, which then complexes with calcium to form calcium bilirubinate. Calcium bilirubinate acts as the nidus for the formation of pigmented stones. Pigment stone formation then leads to recurrent biliary obstruction with the characteristic consequence of suppurative cholangitis. This theory of nutrition associated deficiency of beta-glucuronide has been called into question as definite differences in enzyme levels between patients with gallstones and control subjects are difficult to demonstrate.

Infection in the biliary system from Ascaris lumbricoides or from trematodes, such as Clonorchis sinensis and Opisthorchis viverrini, often results in significant epithelial damage. Clinical and experimental data suggest that coliforms may then result in portal bacteremia by bacterial translocation as a result of this epithelial damage. Repeated portal bacteremia, in turn, results in the cascade of events characterized by biliary stasis, obstruction, and stone formation, which consequently result as RPC.

However, it is more likely that infection and malnutrition act in concert to give rise to RPC.



The underlying mechanism of RPC is unclear. Most experts believe that RPC is initiated by helminthic infection of the bile ducts and/or sludge/stone formation from deficient glucuronidation as a consequence of profound malnutrition. The initial insult(s) to the bile ducts precipitates a cycle of biliary stone formation and infection that results in recurrent episodes of pyogenic cholangitis.




United States

The condition is rare. It often is observed in immigrants from Southeast Asia or from other regions of the world where trematode infections are endemic. Patients who have RPC develop it over time; hence, there does not appear to be a risk of developing RPC for visitors to endemic areas.


The worldwide prevalence of cholangiohepatitis is unclear largely because of the paucity of disease statistics in many parts of the world where this disease is endemic. RPC is prevalent in Hong Kong and East Asia. A case in Turkey was successfully treated with surgery.[1]

Although the arrival of Asian immigrants in the United Kingdom, Australia, Europe, and the United States has resulted in more cases reported in nonendemic areas, the overall incidence in East Asia has been in decline over the last 20 years. Population surveys confirm this trend. The decline in incidence has been credited to the improved economic situation and living standards with the associated westernization of diet.



The prognosis is variable and is directly related to the presence or absence of comorbidities, the presence or absence of liver dysfunction, and the presence or absence of malignancy. In general, the prognosis of patients with cholangiohepatitis is not well documented; however, death occurs in approximately 15-20% of patients over 5-6 years.


Morbidity is related to recurrent biliary infection and may manifest as pancreatobiliary abnormalities, such as pancreatitis, biliary fistulae, hepatic abscesses, and suppurative cholangitis. Consequences of systemic infections and remote foci of infections account for distant or nonpancreatobiliary morbidity.


The complications of RPC are protean; acutely, patients may experience systemic sepsis with all of the potential complications of single and multisystem organ failure and hemostatic dysfunction. Over time, patients may develop cirrhosis with portal hypertension and parenchymal insufficiency. Cholangiocarcinoma is an increasingly well-recognized long-term complication of cholangiohepatitis.

Contributor Information and Disclosures

Praveen K Roy, MD, AGAF Chief of Gastroenterology, Presbyterian Hospital; Medical Director of Endoscopy, Presbyterian Medical Group; Adjunct Associate Research Scientist, Lovelace Respiratory Research Institute

Praveen K Roy, MD, AGAF is a member of the following medical societies: American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.


Rajan Kanth, MD Hospitalist, Ministry Saint Joseph’s Hospital

Rajan Kanth, MD is a member of the following medical societies: American College of Physicians, Society of Hospital Medicine, Nepal Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Chief Editor

Julian Katz, MD Clinical Professor of Medicine, Drexel University College of Medicine

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Additional Contributors

Anil Minocha, MD, FACP, FACG, AGAF, CPNSS Professor of Medicine, Director of Digestive Diseases, Medical Director of Nutrition Support, Medical Director of Gastrointestinal Endoscopy, Internal Medicine Department, University of Mississippi Medical Center; Clinical Professor, University of Mississippi School of Pharmacy

Anil Minocha, MD, FACP, FACG, AGAF, CPNSS is a member of the following medical societies: American Academy of Clinical Toxicology, American Society for Gastrointestinal Endoscopy, American Federation for Clinical Research, American Association for the Study of Liver Diseases, American College of Forensic Examiners Institute, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association

Disclosure: Nothing to disclose.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Patrick I Okolo III, MD, MPH, and previous coauthor Sam Yoselevitz, MD, to the development and writing of this article.

  1. Koklu S, Akkus MA, Tas A, et al. Recurrent pyogenic cholangitis in a case with congenital biliary anomaly. Ann Hepatol. 2012 Mar-Apr. 11(2):268-71. [Medline].

  2. Jeyarajah DR. Recurrent pyogenic cholangitis. Curr Treat Options Gastroenterol. 2004 Apr. 7(2):91-98. [Medline].

  3. Bass N. Sclerosing Cholangitis and Recurrent Pyogenic Cholangitis. Feldman M, Scharschmidt B, Slesinger M, eds. Gastrointestinal and Liver Disease. Philadelphia, Pa: WB Saunders; 1993. Vol 1: 1006-25.

  4. Chan FL, Chan JK, Leong LL. Modern imaging in the evaluation of hepatolithiasis. Hepatogastroenterology. 1997 Mar-Apr. 44(14):358-69. [Medline].

  5. Jain M, Agarwal A. MRCP findings in recurrent pyogenic cholangitis. Eur J Radiol. 2008 Apr. 66(1):79-83. [Medline].

  6. Heffernan EJ, Geoghegan T, Munk PL, Ho SG, Harris AC. Recurrent pyogenic cholangitis: from imaging to intervention. AJR Am J Roentgenol. 2009 Jan. 192(1):W28-35. [Medline]. [Full Text].

  7. Eun HW, Kim JH, Hong SS, Kim YJ. Malignant versus benign hepatic masses in patients with recurrent pyogenic cholangitis: MR differential diagnosis. Abdom Imaging. 2012 Oct. 37(5):767-74. [Medline].

  8. Al-Sukhni W, Gallinger S, Pratzer A, Wei A, Ho CS, Kortan P, et al. Recurrent pyogenic cholangitis with hepatolithiasis--the role of surgical therapy in North America. J Gastrointest Surg. 2008 Mar. 12(3):496-503. [Medline].

  9. Tsui WM, Chan YK, Wong CT, Lo YF, Yeung YW, Lee YW. Hepatolithiasis and the syndrome of recurrent pyogenic cholangitis: clinical, radiologic, and pathologic features. Semin Liver Dis. 2011 Feb. 31(1):33-48. [Medline].

  10. Lee KF, Chong CN, Ng D, et al. Outcome of surgical treatment for recurrent pyogenic cholangitis: a single-centre study. HPB (Oxford). 2009. 11(1):75-80. [Medline]. [Full Text].

  11. Afagh A, Pancu D. Radiologic findings in recurrent pyogenic cholangitis. J Emerg Med. 2004 Apr. 26(3):343-6. [Medline].

  12. American College of Surgeons. Surgical Education and Self-assessment Program (SESAP). Recurrent pyogenic cholangitis. Can J Surg. 2004 Apr. 47(2):121. [Medline].

  13. Carmona RH, Crass RA, Lim RC Jr, Trunkey DD. Oriental cholangitis. Am J Surg. 1984 Jul. 148(1):117-24. [Medline].

  14. Chen MF, Jan YY, Wang CS, et al. A reappraisal of cholangiocarcinoma in patient with hepatolithiasis. Cancer. 1993 Apr 15. 71(8):2461-5. [Medline].

  15. Chen PH, Lo HW, Wang CS, et al. Cholangiocarcinoma in hepatolithiasis. J Clin Gastroenterol. 1984 Dec. 6(6):539-47. [Medline].

  16. Cheng YF, Lee TY, Sheen-Chen SM, Huang TL, Chen TY. Treatment of complicated hepatolithiasis with intrahepatic biliary stricture by ductal dilatation and stenting: long-term results. World J Surg. 2000 Jun. 24(6):712-6. [Medline].

  17. Chijiiwa K, Yamashita H, Yoshida J, Kuroki S, Tanaka M. Current management and long-term prognosis of hepatolithiasis. Arch Surg. 1995 Feb. 130(2):194-7. [Medline].

  18. Cosenza CA, Durazo F, Stain SC, Jabbour N, Selby RR. Current management of recurrent pyogenic cholangitis. Am Surg. 1999 Oct. 65(10):939-43. [Medline].

  19. Digby KH. Common-duct stones of liver origin. Br J Surg. 1930. 17:578-91.

  20. Koga A, Ichimiya H, Yamaguchi K, Miyazaki K, Nakayama F. Hepatolithiasis associated with cholangiocarcinoma. Possible etiologic significance. Cancer. 1985 Jun 15. 55(12):2826-9. [Medline].

  21. Lam SK. A study of endoscopic sphincterotomy in recurrent pyogenic cholangitis. Br J Surg. 1984 Apr. 71(4):262-6. [Medline].

  22. Lee SK, Seo DW, Myung SJ, et al. Percutaneous transhepatic cholangioscopic treatment for hepatolithiasis: an evaluation of long-term results and risk factors for recurrence. Gastrointest Endosc. 2001 Mar. 53(3):318-23. [Medline].

  23. Lee Y, Lee BH, Park JH, Suh CH. Balloon dilatation of intrahepatic biliary strictures for percutaneous extraction of residual intrahepatic stones. Cardiovasc Intervent Radiol. 1991 Mar-Apr. 14(2):102-5. [Medline].

  24. Lim JH. Oriental cholangiohepatitis: pathologic, clinical, and radiologic features. AJR Am J Roentgenol. 1991 Jul. 157(1):1-8. [Medline].

  25. Min HK. Clonorchis sinensis: pathogenesis and clinical features of infection. Arzneimittelforschung. 1984. 34(9B):1151-3. [Medline].

  26. Nakanuma Y, Terada T, Tanaka Y, Ohta G. Are hepatolithiasis and cholangiocarcinoma aetiologically related? A morphological study of 12 cases of hepatolithiasis associated with cholangiocarcinoma. Virchows Arch A Pathol Anat Histopathol. 1985. 406(1):45-58. [Medline].

  27. Ng WT. Pathogenesis of acute cholecystitis and recurrent pyogenic cholangitis. Surg Laparosc Endosc Percutan Tech. 2004 Aug. 14(4):240-1. [Medline].

  28. Saing H, Chan KL, Mya GH, Cheng W, Fan ST, Chan FL. Cutaneous stoma in the roux limb of hepaticojejunostomy (hepaticocutaneous jejunostomy): useful access for intrahepatic stone extraction. J Pediatr Surg. 1996 Feb. 31(2):247-50. [Medline].

  29. Schulman A. Intrahepatic biliary stones: imaging features and a possible relationship with ascaris lumbricoides. Clin Radiol. 1993 May. 47(5):325-32. [Medline].

  30. Sheen-Chen S, Chen W, Eng H, et al. Bacteriology and antimicrobial choice in hepatolithiasis. Am J Infect Control. 2000 Aug. 28(4):298-301. [Medline].

  31. Sperling RM, Koch J, Sandhu JS, Cello JP. Recurrent pyogenic cholangitis in Asian immigrants to the United States: natural history and role of therapeutic ERCP. Dig Dis Sci. 1997 Apr. 42(4):865-71. [Medline].

  32. Stain SC, Incarbone R, Guthrie CR, et al. Surgical treatment of recurrent pyogenic cholangitis. Arch Surg. 1995 May. 130(5):527-32; discussion 532-3. [Medline].

  33. Tanaka M, Ikeda S, Ogawa Y, et al. Divergent effects of endoscopic sphincterotomy on the long-term outcome of hepatolithiasis. Gastrointest Endosc. 1996 Jan. 43(1):33-7. [Medline].

  34. Tang CN, Tai CK, Ha JP, Siu WT, Tsui KK, Li MK. Laparoscopy versus open left lateral segmentectomy for recurrent pyogenic cholangitis. Surg Endosc. 2005 Sep. 19(9):1232-6. [Medline].

  35. Tang CN, Tai CK, Siu WT, Ha JP, Tsui KK, Li MK. Laparoscopic treatment of recurrent pyogenic cholangitis. J Hepatobiliary Pancreat Surg. 2005. 12(3):243-8. [Medline].

  36. Wong WT, Teoh-Chan CH, Huang CT, Cheng FC, Ong GB. The bacteriology of recurrent pyogenic cholangitis and associated diseases. J Hyg (Lond). 1981 Dec. 87(3):407-12. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.